Antibody Drug Conjugates (ADCs) are targeted medicines that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of antibody-drug conjugates is fairly straightforward. When a portion of the antibody-drug conjugate is administered intravenously and binds to a target antigen on the cell surface of the tumor cell, the complex is internalized. Internalized vesicles fuse with other vesicles and enter the endosome-lysosome pathway after internalization. In the lysosome, proteases digest the monoclonal antibody to release free payloads, which then cross the lysosome membrane to enter the cytoplasm and/or nucleus, where they bind to the target molecule, causing cell death.
Market Dynamics
Market players are involved in research and development activities, this could contribute to the growth of the global antibody drug conjugates market over the forecast period. For instance, on April 05, 2021, Exelixis, Inc., a commercially successful oncology-focused biotechnology company, announced that the U.S. Food and Drugs Administration (FDA) accepted their Investigational New Drug Application (IND) to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of XB002 in patients with advanced solid tumors. XB002, as a next-generation tissue factor-targeting antibody-drug conjugate (ADC), has the potential for a higher therapeutic index and a better safety profile than earlier-generation tissue factor-targeting ADCs.
Market players are focused on strategic collaborations and agreements, which is expected to propel the growth of the global antibody drug conjugates market. For instance, on June 17, 2021, Eisai Co., Ltd., a leading global R&D-based pharmaceutical company, and Bristol-Myers Squibb Company, a global biopharmaceutical company, announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the global antibody drug conjugates market. For instance, on September 13, 2020, Gilead Sciences, Inc., a research-based biopharmaceutical company, and Immunomedics, a leader in next-generation antibody-drug conjugate (ADC) technology, announced a definitive agreement under which Gilead will acquire Immunomedics for US$ 88.00 per share in cash. Under the terms of agreement, Gilead will be provided with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2020, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC).
Key features of the study:
- This report provides an in-depth analysis of global antibody drug conjugates market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global antibody drug conjugates market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global antibody drug conjugates market
Detailed Segmentation:
- Global Antibody Drug Conjugates Market, By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- Global Antibody Drug Conjugates Market, By Application :
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- Global Antibody Drug Conjugates Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Antibody Drug Conjugates Market, By Region:
- North America
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Name:
- Adcetris
- Kadcyla
- Besponsa
- Lumoxiti
- Mylotarg
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Hoffmann-La Roche Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Ltd.
- Astellas Pharma
- ADC Therapeutics
- Pfizer, Inc.
- Seagen, Inc.
- Daiichi Sankyo Company Ltd.
- Oxford Biotherapeutics
“*” marked represents similar segmentation in other categories in the respective section.
